Technical Analysis for NGM - NGM Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 14.15 9.27% 1.20
NGM closed up 9.27 percent on Thursday, November 14, 2019, on 1.58 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical NGM trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 9.27%
20 DMA Support Bullish 8.85%
MACD Bullish Centerline Cross Bullish 8.85%
Calm After Storm Range Contraction 8.85%
20 DMA Support Bullish 10.37%

Older signals for NGM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Diabetes Pharmacy Monoclonal Antibodies Obesity Age Related Macular Degeneration Treatment Of Obesity
Is NGM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 19.27
52 Week Low 8.81
Average Volume 146,113
200-Day Moving Average 0.0
50-Day Moving Average 13.3383
20-Day Moving Average 12.795
10-Day Moving Average 12.98
Average True Range 1.0126
ADX 21.48
+DI 23.0882
-DI 21.8099
Chandelier Exit (Long, 3 ATRs ) 11.3622
Chandelier Exit (Short, 3 ATRs ) 12.987799999999999
Upper Bollinger Band 14.0582
Lower Bollinger Band 11.5318
Percent B (%b) 1.04
BandWidth 19.745213
MACD Line 0.1232
MACD Signal Line -0.0475
MACD Histogram 0.1707
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.67
Resistance 3 (R3) 16.47 15.44 16.25
Resistance 2 (R2) 15.44 14.79 15.54 16.11
Resistance 1 (R1) 14.79 14.40 15.12 14.99 15.97
Pivot Point 13.76 13.76 13.92 13.86 13.76
Support 1 (S1) 13.11 13.11 13.44 13.31 12.33
Support 2 (S2) 12.08 12.72 12.18 12.19
Support 3 (S3) 11.43 12.08 12.05
Support 4 (S4) 11.63